Funding Arrangements	9 Months Ended
Sep. 30, 2022
Funding Arrangements [Abstract]
Funding Arrangements	Note 4. Funding Arrangements NIAID Contract In September 2022, the Company was awarded a contract from NIAID to provide Federal funding to support preclinical, Phase 1 studies and other activities to enable the advancement of epetraborole into late-stage development for acute systemic melioidosis and other biothreat pathogens. The Company can receive up to $17.8 million over a base period and seven option periods over a total term 48 months. As of September 30, 2022, funding for an 18-month base period totaling $4.3 million has been committed. The Company did not recognize any income under this agreement during the three and nine months ended September 30, 2022.

Funding Arrangements

9 Months Ended

Sep. 30, 2022

Note 4. Funding Arrangements

NIAID Contract

In September 2022, the Company was awarded a contract from NIAID to provide Federal funding to support preclinical, Phase 1 studies and other activities to enable the advancement of epetraborole into late-stage development for acute systemic melioidosis and other biothreat pathogens. The Company can receive up to $17.8 million over a base period and seven option periods over a total term 48 months. As of September 30, 2022, funding for an 18-month base period totaling $4.3 million has been committed. The Company did not recognize any income under this agreement during the three and nine months ended September 30, 2022.